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Abstract
Background: Fatigue often triggers screening for and treatment of subclinical hypothyroidism. However, data on the impact of levothyroxine 
on fatigue is limited and previous studies might not have captured all aspects of fatigue.
Method: This study is nested within the randomized, placebo-controlled, multicenter TRUST trial, including community-dwelling participants 
aged ≥65 and older, with persistent subclinical hypothyroidism (TSH 4.60–19.99 mIU/L, normal free thyroxine levels) from Switzerland and 
Ireland. Interventions consisted of daily levothyroxine starting with 50 μg (25 μg if weight <50 kg or known coronary heart diseases) together 
with dose adjustments to achieve a normal TSH and mock titration in the placebo group. Main outcome was the change in physical and mental 
fatigability using the Pittsburgh Fatigability Scale over 1 year, assessed through multivariable linear regression with adjustment for country, 
sex, and levothyroxine starting dose.
Results: Among 230 participants, the mean ± standard deviation (SD) TSH was 6.2 ± 1.9 mIU/L at baseline and decreased to 3.1 ± 1.3 with 
LT4 (n = 119) versus 5.3 ± 2.3 with placebo (n = 111, p < .001) after 1 year. After adjustment we found no between-group difference at 1 year 
on perceived physical (0.2; 95% CI −1.8 to 2.1; p = .88), or mental fatigability (−1.0; 95% CI −2.8 to 0.8; p = .26). In participants with higher 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),  
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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fatigability at baseline (≥15 points for the physical score [n = 88] or ≥13 points for the mental score [n = 41]), the adjusted between-group 
differences at 1 year were 0.4 (95% CI −3.6 to 2.8, p = .79) and −2.2 (95% CI −8.8 to 4.5, p = .51).
Conclusions: Levothyroxine in older adults with mild subclinical hypothyroidism provides no change in physical or mental fatigability.
Keywords:  Levothyroxine, Fatigue, Thyroid disease
Subclinical hypothyroidism (SHypo), defined as the presence of an 
elevated serum thyrotropin (TSH) level combined with free thy-
roxine (fT4) level in the normal range (1), affects between 8% and 
18% of adults aged 65  years or older, with a higher prevalence 
among women (2). SHypo is either asymptomatic or can have symp-
toms similar to those observed in overt hypothyroidism. Among 
these, global fatigue (or tiredness, which will be used as synonym 
in the following) is one of the most common causes for thyroid 
hormone testing in general practice and often results in therapy 
(3–5). Nevertheless, evidence from randomized controlled trial 
investigating the effect of levothyroxine (LT4) replacement on fa-
tigue in SHypo is very limited, with conflicting previous data (6–8). 
The TRUST trial (“Thyroid Hormone Therapy for Older Adults 
with Subclinical Hypothyroidism”) is the only trial providing quan-
titative data for tiredness as outcome and is the largest, randomized, 
multicenter trial with the power to detect clinically meaningful bene-
fits from LT4 replacement in older adults with SHypo (6). Its findings 
indicated no effect of LT4 replacement on global fatigue, as assessed 
by the Thyroid Related Quality-of-Life Patient-Reported Outcome 
measure (ThyPRO) (6,9). However, assessing global fatigue without 
taking activity into account might result in misleading conclusions 
since older adults, in particular, tend to adjust their activity levels in 
such a way that perceived fatigue remains tolerable (10). Assessing 
fatigability, a concept which anchors tiredness to a set of activities 
of defined intensity and duration, has proven to be a more sensi-
tive measure for detecting fatigue rather than using global fatigue 
scores (10). In view of the remaining controversy on the benefit of 
LT4 replacement in SHypo regarding symptoms (11,12), this pre-
registered study nested within the TRUST trial aimed at extending 
the TRUST trial findings with this novel concept of fatigability using 
the Pittsburgh Fatigability Scale (PFS) (10,13).
Method
This study is registered on ClinicalTrials.gov (number 
NCT02500342) as a nested study from the TRUST trial performed 
in Scotland, Ireland, the Netherlands, and Switzerland (6). This 
nested study was designed after the recruitment of the main trial 
started since the scale used for outcome measure was published 
afterward (January 2015) (13).
This nested study included the TRUST participants included at 
the two Swiss study centers (Inselspital, Bern University Hospital, 
and Centre Hospitalier Universitaire Vaudois, Lausanne University 
Hospital) and the Irish center (University College Cork, National 
University of Ireland, Ireland) (14). The trial was approved by the 
relevant ethics committees, and participants provided written in-
formed consent.
The TRUST Trial
As previously published (14), the TRUST trial was a multicenter 
randomized, placebo-controlled parallel-group trial that included 
community-dwelling adults aged ≥ 65 years with untreated SHypo. 
In brief, participants were assigned to treatment or placebo group 
through permuted block randomization in a 1:1 ratio with stratifi-
cation for sex, country, and starting dose. SHypo was defined as the 
presence of persistently elevated TSH levels (4.6–19.9 mIU/L) with 
fT4 within the assay reference range. TSH levels counted as persist-
ently elevated if increased at a minimum of two occasions at least 
3 months apart, over a maximum period of 3 years. The intervention 
consisted of daily LT4 doses, starting with 50 μg (or 25 μg in par-
ticipants with bodyweight < 50 kg or with known coronary heart 
diseases, that is, symptoms of angina pectoris, or previous myocar-
dial infarction), followed by dose adjustments to achieve a TSH level 
within the reference range (6). Blinding of participants was ensured 
by matching LT4 and placebo tablets as well as mock titrations 
in the placebo group, and blinding of clinicians and study centers 
through remote laboratory analysis of blood samples for TSH and 
dose titration as per computer algorithm.
The study was funded by the European Union FP7 and by the 
Swiss National Science Foundation (SNSF) for this nested study. LT4 
as well as matching placebo were supplied free of charge by Merck 
KGaA (Darmstadt, Germany). The funders, sponsors (NHS Greater 
Glasgow and Clyde Health Board and University of Glasgow, United 
Kingdom; University College Cork, Ireland; Leiden University 
Medical Center, the Netherlands; and University of Bern and Bern 
University Hospital, Switzerland) and Merck had no influence on the 
main and nested studies’ designs, analyses or reporting.
The primary outcomes of this study were defined prior to data 
collection as the mean follow-up scores for mental and physical fat-
igability, measured by the PFS (13), after 1 year of follow-up with 
adjustment for baseline scores. Exploratory secondary outcome 
measures (that were not pre-specified) were the number of partici-
pants reporting higher physical (≥15 points) or mental fatigability 
(≥13 points) after 1 year of treatment with adjustment for baseline 
numbers, based on previously established cut points (15).
Pittsburgh Fatigability Scale
The PFS is a reliable, sensitive scale, and the first-validated self-
report tool to measure perceived fatigability in older adults (13). It 
is a 10-item questionnaire asking the participants to estimate the 
physical and mental fatigability they expect or image they would 
have after performance of different activities of specific intensity 
and duration. The two independent subscores (physical and mental) 
range from 0 to 50, with higher scores indicating greater fatigability. 
The cut points for higher fatigability are set at ≥15 points for the 
physical PFS subscore and at ≥13 points for the mental PFS subscore 
(15,16). The minimal clinically important difference is estimated at 
2 to 3 points (13,17). The PFS has been translated into German and 
French, including two forward translations, synthesis of translations, 
and two back-translations.
Statistical Analysis
We performed the main analysis in a modified intention-to-treat 
population, which included all participants with outcome of interest, 
and not more than three missing answers in the PFS. For up to 
three missing items, we imputed data using an imputation method 
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published by the scale’s developers (18). Imputed data were based 
on the mean value of an individual’s complete responses with ad-
justments for varying intensity levels of the different activities, sex 
differences as well as differences in reported fatigability levels be-
tween participants who have versus those who have not done each 
specific activity (18). Multivariable linear regression was conducted 
for the physical and mental PFS scores at 1 year with adjustment 
for the stratification variables used for the randomization (country, 
sex, starting dose of LT4), as well as for corresponding PFS base-
line values. Goodness of model fit was assessed through distribution 
plots of residuals and scatter plots of standardized residuals against 
predicted values.
The between-group difference in number of participants with 
higher fatigability at follow-up was assessed using multivariable lo-
gistic regression adjusting for the same variables as described above.
We conducted several sensitivity analyses: (a) in a population 
limited to participants with complete outcome data (participants 
who have answered to all the questions from baseline and follow-up 
questionnaire), (b) using the inverse probability weighting method in 
order to adjust for a possible attrition bias due to loss to follow-up 
(12 months missing primary outcomes) (19); the covariates included 
in the logistic regression model to estimate inverse probability 
weightings were chosen based on clinical judgment: age, body-mass 
index, country, sex and the number of comorbidities, (c) in partici-
pants who, after 1 year, adhered to the trial regimen in accordance 
with the protocol (per-protocol population), (d) only in participants 
who reported higher fatigability at baseline, (e) two exploratory sen-
sitivity analyses, one excluding participants with diabetes and one 
adjusting for the presence of diabetes, to adjust for the baseline im-
balance of diabetes prevalence between the groups, (f) an analysis of 
square-root transformed data to account for skewness in baseline 
scores, (g) in participants with TSH levels in the upper quartile.
Power calculation (Analysis of covariance [ANCOVA] method) 
for 110 participants per allocation group assuming a standard devi-
ation (SD) of 9 in baseline fatigability and a baseline to follow-up 
correlation of 0.7 resulted in a 93.3% power to detect a difference 
of three points (minimal clinically important difference) in the mean 
follow-up fatigability scores at a two-sided alpha level of 0.05 (20).
Results
Trial Population
The study flowchart is shown in Figure 1. Participants were enrolled 
from January 2014 to December 2015. The last participant com-
pleted the study follow-up in November 2016. From 1,273 partici-
pants screened, most reverted to normal TSH before randomization 
and 276 participants were randomized (n = 142 allocated to LT4) 
(6). Fifty-six participants were randomized before the present nested 
study began. Overall, 38 participants had missing 12-month PFS. 
Thirteen withdrew from the study, two participants died, one par-
ticipant did not attend follow-up for unknown reasons, and 22 par-
ticipants attended the follow-up visit but did not answer the PFS 
questions (Figure 1). These participants with missing 12-month PFS 
were similar in baseline physical and mental fatigability as well as 
age, BMI, number of comorbidities, and the median number of con-
comitant medications to the participants who were included. Of 
the 238 participants who had follow-up data, 22 (10 from the LT4 
group, 12 from the placebo group) participants had missing answers 
in the baseline or/and the follow-up PFS physical subscore, of these, 
eight participants (three in the LT4 group, five in the placebo group) 
were not imputed because of more than three missing answers, 
while the remaining 14 were imputed. This resulted in a modified 
intention-to-treat population of 119 participants in the LT4 and 111 
in the placebo group, for both subscores.
Table 1 summarizes the baseline characteristics from all random-
ized participants (n = 276). Characteristics were well balanced between 
the two groups except for diabetes mellitus (p = .12), which was more 
prevalent in the LT4 group. In the LT4 group, 17 (12.0%) participants 
started with a lower dose of 25 µg. The mean LT4 dose in the LT4 
group was 47 µg (ranging from 25 µg to 50 µg) at baseline and 48 µg 
(range 0 µg to 100 µg) at 1-year follow-up. The mean ± SD TSH was 
6.2 ± 1.9 mIU/L at baseline and decreased to 3.1 ± 1.3 in the LT4 group 
versus 5.3 ± 2.3 in the placebo group (p < .001) after 1 year (Table 2).
Fatigability
Baseline perceived physical and mental fatigability between the LT4 
and the placebo group differed by 3.6 points (p  =  .003) and 2.3 
points (p = .023), respectively (Table 2). Baseline fatigability imbal-
ance was not associated with baseline diabetes imbalance.
The mean follow-up PFS physical score was 14.8 ± 9.6 in the LT4 
group and 12.4 ± 9.3 in the placebo group with an adjusted between-
group difference of 0.2 (95% CI −1.8 to 2.1, p =  .88). The mean 
follow-up PFS mental score was 6.0 ± 7.8 in the LT4 and 6.0 ± 8.0 
in the placebo group, respectively, with an adjusted between-group 
Figure 1. Randomization and follow-up. 1The Pittsburgh Fatigability Scale 
(PFS) has two separate subscores for mental and physical fatigability, 
each ranging from 0 to 50 with higher scores indicating greater fatigability. 
2Eleven participants in the levothyroxine group and 11 participants in the 
placebo group had a follow-up visit but did not answer the PFS-questions 
due to administrative reasons, n  = 1 participant in the placebo group had 
a follow-up visit but did not answer the PFS-questions due to unknown 
reasons. These missing outcomes were accounted for in sensitivity analysis 
(Inverse probability weighting [IPW] analysis). 3Thirteen participants 
withdrew, in eight cases due to participants’ decision, in three cases due to 
adverse events, in one case due to physician recommendation for unknown 
reason and in one participant the reason is unknown. 4One participant died 
from a septic shock due to a colon perforation combined with a segmental 
pulmonary embolism left and one participant died from dehydration due 
to an aspiration pneumonia with acute hypoxemia and progression of 
cell carcinoma of the hypopharynx. Both deaths were not related to the 
medication. 5Participants with more than three missing questions or lacking 
information whether the activity has been done or not for a missing answer, 
as defined in the rules to analyze PFS (13,18).
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difference of −1.0 (95% CI −2.8 to 0.8, p = .26) (Table 2). Fit of the 
linear regression model was good.
Secondary analysis for binary outcomes distinguishing between 
participants with lower fatigability and those with higher fatigability 
(ie, PFS as a binary categorical variable) resulted in nonsignificant 
findings, with an odds ratio of 1.0 (95% CI 0.5 to 1.8) for the phys-
ical fatigability and an odds ratio of 0.6 (95% CI = 0.3 to 1.4) for 
the mental fatigability (Table 2).
Sensitivity analyses in the participants with complete data did 
not find a significant difference between the groups (Supplementary 
Table 1). In order to account for the participants not having 12-month 
PFS, we conducted sensitivity analyses using inverse probability 
weighting, and the results remained robust. Sensitivity analyses in 
the per-protocol population did not find a significant difference be-
tween the groups (Supplementary Table 1). Furthermore, including 
only participants with higher fatigability at baseline did not result in 
significant between-group differences either. Because of the baseline 
imbalance in diabetes, we performed sensitivity analyses adjusting 
for the presence of diabetes and excluding participants with diabetes 
and the results did not change. Also, performing sensitivity analyses 
using square-root transformed data did not show benefit of LT4 re-
placement. In a population limited to participants with TSH levels in 
the upper quartile (≥6.76 mIU/L), findings were similar.
Discussion
This nested study within a randomized, placebo-controlled, parallel-
group, double-blind multicenter trial in 230 participants aged 
≥ 65  years with SHypo did not show a significant benefit of LT4 
replacement on physical or mental fatigability after 1 year of treat-
ment, using a more sensitive scale (10) and assessing both, physical 
and mental fatigability, instead of global fatigue as measured in the 
main TRUST trial (6).
Previous data on the impact of LT4 on fatigue are limited and 
conflicting. Even though fatigue is a very common symptom in 
SHypo and often leads to LT4 prescription (4,5), a recent systematic 
review showed that large randomized controlled trials investigating 
the benefit of LT4 replacement on fatigue in SHypo are lacking (8). 
The only trial, which provided quantitative data for the outcome of 
fatigue/tiredness, was the TRUST trial. Using the ThyPRO question-
naire to assess tiredness (seven items), the TRUST trial did not find a 
benefit of LT4 replacement on tiredness in older adults with SHypo. 
Nevertheless, results were in contrast to the findings of Razvi et al. 
who reported a benefit of LT4 replacement in SHypo (7). In their 
randomized, crossover trial in 100 participants with SHypo (mean 
age 53.8 ± 12.0 years), the authors reported that the proportion of 
participants with tiredness decreased from 89% to 78% under LT4 
replacement, but did not provide measures of precision (such as con-
fidence intervals) and how tiredness was assessed. However, their 
study differs from ours with respect to the lower mean age of partici-
pants and the higher daily LT4 dose (100 μg vs a mean dose of 47 µg 
at baseline in our study). It would be interesting to compare the fat-
igability levels of our study population to the fatigability level of a 
comparable population of older adults, but there are very limited 
population-based data currently available for comparison because 
our study was early in using the PFS.
Table 1. Baseline Characteristics of all Participants Randomized (n = 276)
Characteristic Placebo (N = 134) Levothyroxine (N = 142)
Age (y)   
 Mean ± SD 73.5 ± 6.3 73.9 ± 5.1
 Range 65.1–92.9 65.3–88.6
Female sex—no. (%) 60 (44.8) 62 (43.4)
White race—no. (%)a 132 (99) 141 (99)
Standard housing—no. (%)b 130 (97) 140/142 (99)
Weight <50 kg—no. (%) 3 (2) 3 (2)
Body-mass index, kg/m2, mean ± SDc 27.5 ± 4.6 28.0 ± 4.6
Previous medical conditions and clinical descriptors—no. (%)
 Ischemic heart diseased 13 (9.7) 14 (9.9)
 Atrial fibrillation 16 (11.9) 15 (10.7)
 Hypertension 8 (6.0) 4 (2.8)
 Diabetes mellituse 14 (10.4) 24 (16.9)
 Osteoporosis 17 (12.7) 14 (10.1)
 Current smokingf 12 (9.0) 8 (5.6)
No. of concomitant medicines—median (IQRg) 4 (2–6) 5 (3–5.5)
Laboratory results   
 Thyrotropin—mIU/L, mean ± SD 6.31 ± 2.00 6.12 ± 1.90
  Median (IQRg) 5.70 (5.02–6.79) 5.60 (5.04–6.80)
  Range 4.60–17.00 4.62–16.76
 Free thyroxine—pmol/L, mean ± SD 13.5 ± 1.9 13.7 ± 2.0
Levothyroxine dose of 25 μg at randomization (%) 14 (10.5) 17 (11.9)
Notes: aRace was reported by the participants.
bStandard housing was defined as non-sheltered community accommodation, whereas sheltered housing means a purposed-built grouped housing for older 
persons.
cCalculated as weight (kilograms) divided by squared height (meters).
dDefined as history of angina pectoris or previous myocardial infarction.
ep = .12.
fDefined as current smoking at the time of baseline exam.
gIQR denotes interquartile range.
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Strengths and novelty of our study were the use of a valid-
ated scale that measures the novel construct of fatigability and 
the consideration of both the physical and mental dimensions of 
fatigability (10,13). Prevalence of global fatigue varies widely de-
pending on measurement tools, population characteristics, and 
cutoff points chosen to distinguish between fatigued and non-
fatigued participants (21,22). It is, therefore, desirable to bring 
more objectivity into tiredness evaluation. Fatigability is a concept 
that classifies fatigue in relation to a defined activity of a specific 
duration and intensity (10). This conceptualization might lead to 
a less biased and more objective measure of fatigue than a global 
fatigue score (13). The classification of fatigue in relation to spe-
cific activities is especially helpful in older adults, as these indi-
viduals tend to adjust their activity level (eg, by slowing down or 
shortening the task duration) in order to maintain their perceived 
fatigue in a tolerable range (13). It is thus possible that two individ-
uals differing in their daily activities (with one having a very active 
lifestyle and the other a sedentary way of living) report the same 
tiredness level for the last month. The construct of fatigability is 
adapted to take the bias of “self-pacing” into account (10,13). The 
PFS is furthermore the only scale taking into account the multidi-
mensionality of fatigability by distinguishing between mental and 
physical fatigability (23). Mental fatigability—or self-reported cog-
nitive tiredness related to specific activities—is rarely recognized by 
the medical community (24). Thus, this study is the first to test the 
effect of LT4 treatment on both physical and mental fatigability in 
older subjects with SHypo.
This study has limitations. First, participants were included inde-
pendent of their baseline fatigability, leading to a proportion of 38% 
with higher physical fatigability (≥15 points) and 18% with higher 
mental fatigability (≥13 points). It is possible that findings could 
differ in a population of (highly) fatigued participants. A sensitivity 
analysis, including only these participants with higher fatigability, 
did not reveal a reduction in fatigability level after treatment. Second, 
14% (n = 38) of participants did not have 12-month PFS measure-
ments. However, these participants had similar characteristics to 
the participants who did have 12-month PFS and the proportion 
was balanced between the groups. In particular, these subjects had 
baseline scores in physical and mental fatigability that did not differ 
from the participants included in the main analysis. Furthermore, 
results were robust in a sensitivity analysis using inverse probability 
weighting to account for possible bias due to missing outcomes (19). 
Third, the scores for physical and mental fatigability were unbal-
anced between the two groups at baseline. As analyses were adjusted 
for baseline scores, this imbalance at baseline should not be expected 
to impact the results. Fourth, only participants ≥ 65 years were in-
cluded. Fifth, participants with TSH levels >10 mIU/L accounted for 
4% of the study population. Thus, the findings may not be general-
izable to individuals with TSH levels >10 mIU/L. Finally, the mean 
TSH level in the LT4 replacement group was 2.95 mIU/L after 1 year 
of treatment. We could not exclude that fatigability would have de-
creased more under a more aggressive LT4 regimen, but potentially 
at the cost of harms from overtreatment, such as atrial fibrillation or 
fractures (25–28).
Conclusion
Over a 1-year follow-up, normalization of TSH levels through LT4 
replacement in people aged ≥ 65 years did not show a benefit on 
perceived physical and mental fatigability compared to placebo. The 
same finding was shown for participants with higher fatigability at 
baseline. In line with the findings from the TRUST trial on global 
fatigue (6), which was the largest randomized controlled trial on the 
treatment of SHypo, our results do not provide evidence in favor 
of LT4 replacement to reduce fatigability or fatigue in older adults 
with SHypo.
Table 2. Thyroid Function, Physical, and Mental Fatigability at Baseline and After 1 Year
Variable
Baseline At 1 year
Levothyroxine 
(N = 119)
Placebo 
(N = 111)
Levothyroxine 
(N = 119)
Placebo 
(N = 111)
Thyrotropin—mIU/L 6.08 ± 1.80 6.29 ± 2.01 3.08 ± 1.32 5.30 ± 2.34   
Median (IQR) 5.56 (5.04 to 6.62) 5.72 (5.06 
to 6.76)
2.95 (2.26 to 3.77) 4.8 (3.62 to 
6.57)
  
Primary Outcomes     Adjusted Between-
Group Difference 
(95% CI)
p Value
 PFS physical score (SD)a 14.7 ± 9.3 11.1 ± 9.1 14.8 ± 9.6 12.4 ± 9.3 0.2 (−1.8 to 2.1) .88b
 PFS mental score (SD)a 7.4 ± 8.0 5.1 ± 6.9 6.0 ± 7.8 6.0 ± 8.0 −1.0 (−2.8 to 0.8) .26b
Secondary Outcomes     Adjusted Odds 
Ratio (95% CI)
p Value
  Participants with higher 
physical fatigability (%)c
55 (46.2) 33 (29.7) 52 (43.7) 41 (36.9) 1.0 (0.5 to 1.8) .88d
  Participants with higher 
mental fatigability (%)c
27 (22.7) 14 (12.6) 19 (16.0) 20 (18.0) 0.6 (0.3 to 1.4) .23d
aThe Pittsburgh Fatigability Scale (PFS) physical and mental subscores range from 0 to 50 with higher scores indicating greater fatigability. Crude means are 
reported.
bp-value generated through multiple linear regression model for the follow-up scores adjusted for PFS baseline scores, sex, country and starting levothyroxine 
dose.
cThe cut points for higher fatigability are set at ≥15 points for the physical PFS subscore and at ≥13 points for the mental PFS subscore (13,15), as previously 
established.
dp-value generated through multiple logistic regression model for the number of participants with higher fatigability at follow-up adjusted for number of parti-
cipants with higher fatigability at baseline, sex, country and starting levothyroxine dose.
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Supplementary Material
Supplementary data are available at The Journals of Gerontology, 
Series A: Biological Sciences and Medical Sciences online.
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